Autolus Therapeutics (AUTL) Enterprise Value (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Enterprise Value for 9 consecutive years, with -$300.7 million the latest figure, recorded in Q4 2025.

• Quarterly Enterprise Value rose 48.86% year-over-year to -$300.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$300.7 million (up 48.86% YoY) and the FY2025 annual result came in at -$300.7 million, up 48.86% from the prior year.
• Enterprise Value improved to -$300.7 million in Q4 2025 per AUTL's latest filing, from -$367.4 million in the prior quarter.
• Over the last five years, Enterprise Value for AUTL reached as high as -$163.4 million in Q3 2022 and fell as low as -$759.5 million in Q1 2024.
• A 5-year average of -$373.6 million and a median of -$309.3 million in 2021 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2021 — Enterprise Value tumbled 39426.21% — and 2025, when it surged 48.86%.
• Year by year, Enterprise Value stood at -$310.7 million in 2021, then declined by 23.2% to -$382.8 million in 2022, then surged by 37.21% to -$240.3 million in 2023, then plunged by 144.67% to -$588.0 million in 2024, then jumped by 48.86% to -$300.7 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$300.7 million, -$367.4 million, and -$454.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.